The $32 Price Had Nothing Behind It: What iTonic Holdings' Collapse Reveals About Micro-Cap Vulnerability

On July 29, 2025, a stock trading at $32 per share fell 95% in a single afternoon. Trading halted at least eight times. By closing bell, the shares had settled at $1.65, erasing roughly $725 million of paper market capitalization. The company was Pheton Holdings Ltd — now called iTonic Holdings Ltd, trading under the ticker ITOC.

The collapse did not come from a lost contract, a failed drug trial, or a macroeconomic shock. It came from the disappearance of a rumor.

Online promoters had been circulating claims that Gilead Sciences planned to acquire Pheton on August 6, 2025. A research firm called Bear Cave published a report that morning calling the rumor fabricated and the stock a pump-and-dump vehicle. The market absorbed the correction in minutes.

Three days later, Pheton issued a press release of its own: "We have had no contact with Gilead, and any statements or reports suggesting otherwise were and are entirely false and fabricated."

The story works until you look at the numbers. The $32 price implied a market capitalization of about $765 million for a company that generated $628,591 in revenue during fiscal 2023 — roughly the annual salary of one mid-level employee at a large healthcare company. That is not a valuation gap. That is the absence of a valuation.

The Anatomy of a Micro-Cap Mirage

Pheton Holdings began publicly trading on September 5, 2024, at an IPO price of $4.00 per share, raising $9 million in gross proceeds. It is a Cayman Islands holding company whose principal operation is a Beijing-based business founded in 1998 that develops treatment planning software for brachytherapy, a form of radiation therapy used to treat cancer.

The financials from before the offering tell a compact story. In 2021, the company reported $702,776 in revenue and a net income of $192,462. In 2022, revenue fell to $679,777 with $83,980 in net income. In 2023, revenue dropped again to $628,591, and the company turned to a net loss of $241,217. At the end of that fiscal year, total assets were $1.6 million. Cash on hand was $227,450.

The IPO prospectus disclosed two material weaknesses in internal controls over financial reporting at the operating subsidiary. It also noted that the chairman would beneficially own approximately 95.83% of voting power after the offering, and that the company operated under a dual-class share structure: Class B shares carried 20 votes per share versus one vote for Class A.

The auditor was Marcum Asia CPAs LLP, headquartered in New York but with audit working papers located in China — a structure that, as the prospectus itself warned, created uncertainty about whether the PCAOB could inspect the firm's records. The underwriter was Pacific Century Securities LLC, which charged a 7% discount plus up to $250,000 in additional expenses.

None of these facts, individually, is a crime. But together they describe a structure that is extraordinarily vulnerable to price manipulation. Nearly 96% insider ownership means a tiny public float. A dual-class structure means outside investors have no governance leverage. Tiny revenue means the stock price cannot be anchored to fundamentals. Material control weaknesses mean the numbers in the filing themselves carry risk. When a rumor reaches this kind of stock, there is nothing large enough to argue with it.

The Pattern Beneath the Stock

Bear Cave was not guessing when it flagged Pheton. The research firm had documented the same mechanics playing out across other Chinese-listed micro-caps. Ostin Technology surged on rumors of an acquisition by Universal Display Corp, then fell 94%. China Liberal Education Holdings rallied on Stride merger speculation, then shed 98%. Jayud Global Logistics climbed on rumors of a Matson deal, then dropped 95%.

The pattern is identical: a tightly held, low-float stock on Nasdaq; fabricated M&A rumors spread through social media and chat groups, often by people impersonating financial professionals; a parabolic price move with no corporate announcement to support it; a sudden collapse when someone punctures the rumor; and trading halts that extend the damage.

The class action lawsuit filed against iTonic Holdings covers the period from September 5, 2024, through July 29, 2025. The complaint alleges that the company and its underwriter and auditor failed to disclose the material risk that its stock was being targeted by a manipulation scheme, and that positive statements about the company's business were misleading in light of that undisclosed risk. The complaint names the underwriter and auditor as defendants, alleging they had participated in a series of foreign micro-cap listings that became targets of similar schemes.

The lawsuit is at an early stage. The lead plaintiff deadline is September 28, 2026. No court has ruled on the merits. The company denied involvement in the manipulation and committed to working with regulators.

But the evidence ladder here does not require proving that Pheton orchestrated the pump. The legal theory is simpler: the company sold shares to the public through an offering that warned about many risks but did not warn about the one that actually destroyed shareholder value — the realized risk of a manipulation scheme. Whether that omission rises to the level of securities fraud is for the court to decide. What is visible now is the economic outcome.

What the Company Does Now

After the crash, Pheton tried to reposition. In December 2025, it announced it had acquired a 51% stake in iTonic Corporation, a U.S. home-health AI company, paying with 4 million newly issued Class A shares and warrants to buy up to 3 million more. The name changed to iTonic Holdings Ltd in January 2026, and the ticker shifted to ITOC.

The company has since been developing an AI-powered cloud treatment planning platform and issuing progress updates. The latest public financial snapshot shows trailing twelve-month revenue of about $520,000 — not meaningfully different from where the business was three years ago. The stock trades around 29 cents, more than 90% below the IPO price and nearly 99% below the manipulated peak.

Nasdaq has given the company another 180-day extension to regain compliance with its minimum bid price rule. The clock now runs to October 19, 2026. If the stock does not sustain a price of $1.00 or above for 10 consecutive business days during that window, delisting is the likely outcome.

The Shareholder Invoice

Here is what the arithmetic demands. The company raised $9 million at $4 per share. Investors who bought near the $32 peak saw that position lose 95% of its value in one day. Those who purchased between $1 and $4 during the class period have filed for recovery. The current market cap, at roughly 29 cents per share, puts the entire company at a level below what the IPO raised in cash alone.

The shareholder invoice is not a legal conclusion. It is a measurement: every dollar of valuation above the underlying business was paid for speculation, and the speculation turned out to be a lie someone else told. The company itself may be operating legitimately — developing niche cancer-treatment software in Beijing, trying to build an AI platform, fighting to stay listed. But the gap between the business and the price tells the whole story.

A red flag asks a question. In this case, the question was whether a company with $628,000 in annual revenue could trade at a $765 million market cap. The answer is no. The more important question is whether the offering should have warned investors that its own structural vulnerabilities — tiny float, near-total insider control, material weaknesses, and the history of similar micro-cap schemes — made it the kind of stock that manipulators target. That question is now in the hands of a court.

The next settling event is the Nasdaq compliance deadline of October 19, 2026, and the lead plaintiff appointment in the class action on the same date. One determines whether the stock survives as a listed security. The other determines whether shareholders can recover the difference between what they paid and what the stock was worth when the rumor ended.